News Stories

SILVER SPRING, Md. – National Lipid Association Board Member Lori Alexander, MSHS, RD, CCRC, CLS, FNLA testified on Thursday, May 10 in front of the Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee on behalf of familial chylomicronemia patients. The committee held a hearing regarding the safety and efficacy of a new treatment for FCS, volanesorsen.

Chicago-area cardiologist assumes role during NLA Scientific Sessions in Las Vegas

ORLANDO (March 10, 2018) – The ODYSSEY OUTCOMES trial results, announced today at the American College of Cardiology 67th Annual Scientific Sessions in Orlando, revealed the addition of alirocumab to maximally tolerated statin significantly reduced major adverse cardiovascular events (MACE) compared to those on maximally tolerated statin and placebo.